An Open-Label Study to Determine the Safety and Efficacy of Alefacept as Monotherapy in Subjects With Chronic Plaque Psoriasis Who Have Failed to Respond to Anti-TNF Therapy.

Trial Profile

An Open-Label Study to Determine the Safety and Efficacy of Alefacept as Monotherapy in Subjects With Chronic Plaque Psoriasis Who Have Failed to Respond to Anti-TNF Therapy.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 21 Feb 2013

At a glance

  • Drugs Alefacept (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Feb 2013 Last checked against ClinicalTrials.gov record.
    • 29 Sep 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top